Affordable Access

deepdyve-link
Publisher Website

Post-translational modification of SOX family proteins: Key biochemical targets in cancer?

Authors
  • Williams, Charles A C1
  • Soufi, Abdenour1
  • Pollard, Steven M2
  • 1 MRC Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, EH16 4UU, Edinburgh, United Kingdom. , (France)
  • 2 MRC Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, EH16 4UU, Edinburgh, United Kingdom. Electronic address: [email protected] , (France)
Type
Published Article
Journal
Seminars in Cancer Biology
Publisher
Elsevier
Publication Date
Dec 01, 2020
Volume
67
Issue
Pt 1
Pages
30–38
Identifiers
DOI: 10.1016/j.semcancer.2019.09.009
PMID: 31539559
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Sox proteins are a family of lineage-associated transcription factors. They regulate expression of genes involved in control of self-renewal and multipotency in both developmental and adult stem cells. Overexpression of Sox proteins is frequently observed in many different human cancers. Despite their importance as therapeutic targets, Sox proteins are difficult to 'drug' using structure-based design. However, Sox protein localisation, activity and interaction partners are regulated by a plethora of post-translational modifications (PTMs), such as: phosphorylation, acetylation, sumoylation, methylation, and ubiquitylation. Here we review the various reported post-translational modifications of Sox proteins and their potential functional importance in guiding cell fate processes. The enzymes that regulate these PTMs could be useful targets for anti-cancer drug discovery. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times